Clinical Trials Logo

Filter by:
NCT ID: NCT06382662 Recruiting - Clinical trials for Cognitive Impairment

Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition

Start date: April 15, 2024
Phase: Phase 4
Study type: Interventional

Every participant will receive active study drug and one (1 )comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. There will be ( four (4) visits.

NCT ID: NCT06384365 Recruiting - Taste, Altered Clinical Trials

Interaction of Inflammation, Taste Perception and Preferences as a Function of Physical Activity and Body Composition

Start date: April 15, 2024
Phase:
Study type: Observational

The aim of this study is to investigate whether differences in taste perception and preference behavior can be attributed to inflammatory processes induced by physical activity. The focus will be on sweet taste and the perception of fat. A non-invasive, observational study design will be used.

NCT ID: NCT06384885 Recruiting - Clinical trials for Swimming Induced Pulmonary Edema

Ultrasound Investigation Into Swimming Induced Pulmonary Edema in Open Water Swimming Athletes

SIPE
Start date: April 15, 2024
Phase:
Study type: Observational [Patient Registry]

Swimming-induced pulmonary edema (SIPE) is a potentially life-threatening condition that can affect swimmers of all abilities. The pathophysiology is not well understood and early identification strategies are not established. Handheld ultrasound is a validated tool for the identification of pulmonary edema and is not well-studied in this population. Understanding the incidence of signs of pulmonary edema and its usefulness as a sign of early pulmonary edema would be beneficial This study evaluates triathletes and open water swimmers at endurance events. A validated protocol for lung ultrasound is used to identify the signs of pulmonary edema. The findings will be analyzed for differences in experience level, type of athlete, gender, age, and environmental factors. The findings may then be used in the future to aid in the early identification and treatment of athletes and military personnel in similar situations to decrease morbidity and mortality.

NCT ID: NCT06385470 Recruiting - Clinical trials for Childhood Apraxia of Speech

Treatment of Cantonese Speakers With Childhood Apraxia of Speech

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

The proposed study aims to investigate the efficacy of the Dynamic Temporal and Tactile Cueing treatment in Cantonese-English bilingual speakers with childhood apraxia of speech.

NCT ID: NCT06387212 Recruiting - Skin Inflammation Clinical Trials

35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.

NCT ID: NCT06387823 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS

STAR
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of Sivelestat sodium and dexamethasone in the treatment of patients with moderate to severe ARDS. The main questions it aims to answer are: - Is Sivelestat sodium more effective in the treatment of patients with moderate to severe ARDS compared with placebo? - Is dexamethasone more effective in the treatment of patients with moderate to severe ARDS compared with placebo? Participants will receive Sivelestat sodium, dexamethasone or placebo. Researchers will compare the efficacy and safety of Sivelestat sodium, dexamethasone and placebo.

NCT ID: NCT06392828 Recruiting - Clinical trials for Cardiovascular Diseases

EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases

Endo-NAFLD
Start date: April 15, 2024
Phase:
Study type: Observational

Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental. Non-alcoholic fatty liver disease (NAFLD) has emerged recently as a potential mediator of CVD onset and progression. The hypothesis is that NAFLD can be a predictive CVD risk factor, independent of other classical and well-known risk factors. Preliminary epidemiological studies suggested that the fat infiltration in the liver mirrored the cardiometabolic status of the patient. But recent studies postulate that NAFLD could be a potential independent predictor of vascular injury. The mechanisms that link liver function and endothelial damage include modulation of adipose tissue function, lipid metabolism regulation or glycemic homeostasis, among others. But new mechanisms that could link NAFLD and ECV are emerging. The synthesis of ketone bodies in the liver is closely related to the cardiovascular system function. Ketone bodies can provide up to 50% of energy required by specific tissues. Plasma concentration of β-hydroxybutyrate is a biomarker of NAFLD. Plasma β-hydroxybutyrate and acetoacetate levels are also inversely associated with endothelial injury. Other biomarkers on endothelial damage like von Willebrand factor, ICAM, VCAM or coagulation factors (Factor VIII) can be used to stratify patients according to the risk of CVD. The improvement in the sensitivity, specificity and accuracy of scores such as FLI, HIS and FIB-4 and non-invasive techniques such as elastography allow the study of the relationship between liver disease and other comorbidities. The aim is to evaluate the potential of NAFLD to stratify patients according to the risk of CVD and to investigate the molecular mechanisms linking NAFLD and CVD.

NCT ID: NCT06394453 Recruiting - Newborn Asphyxia Clinical Trials

Is Feeding During Therapeutic Hypothermia Safe and Can Improve Outcomes in Infants With Hypoxic-ischaemic Encephalopathy

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

Therapeutic hypothermia (TH) is the standard of care for newborns with moderate to severe hypoxic-ischaemic encephalopathy (HIE) born at 35 weeks or more of gestation. Many neonatal units do not use enteral feeding during TH, in fear of increased risk of complications. Withholding enteral feedings during TH lacks supporting evidence. The aim of the study is to determine if enteral feeding during TH in patients with HIE is safe and assess its effects. Investigators will perform multicenter randomized controlled study in level III neonatal intensive care units on infants qualified for TH. Infants will be randomized into 2 groups: (1) unfed during 72 hours of TH; (2) fed group, which will start receive enteral feeding with mother milk or human donor breast milk at 10 ml/kg/day during first day of TH, 20 ml/kg/day during second day, 30 ml/kg/day during third day. The primary outcome will be (1) combined necrotizing enterocolitis or death, (2) length of hospital stay. The secondary outcomes will be (1) time to full enteral feeding, (2) late-onset sepsis, (3) Test of Infant Motor Performance scoring, (4) MRI scoring, (5) MR spectroscopy parameters.

NCT ID: NCT06398704 Recruiting - Clinical trials for Geriatric Individuals

Investigation of Inspiratory Muscle Strength and Cardiorespiratory Fitness in Sarcopenic Individuals

Start date: April 15, 2024
Phase:
Study type: Observational

The aim of our study is to examine the effects of sarcopenia and dynapenia on inspiratory muscle strength and cardiorespiratory fitness in geriatric individuals.

NCT ID: NCT06400693 Recruiting - Airway Management Clinical Trials

Templates as Cognitive Aids in Emergency Airway Equipment Preparation: the Template Airway Trial

TemplateAirway
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

Comparison of preparation times (in seconds) for emergency airway management (equipment only) with and without a template.